Cargando…
SUN-416 Ipilimumab Associated Hypophysitis and Thyroiditis
INTRODUCTION Ipilimumab, an anti cytotoxic T lymphocyte associated antigen 4 (CTLA 4) antibody, is approved for use in advanced melanoma based upon survival benefit. Anti CTLA 4 antibodies are associated with a myriad of side effects. CLINICAL CASE A 65 year old male with stage 3A malignant melanoma...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552704/ http://dx.doi.org/10.1210/js.2019-SUN-416 |